Tendinous disorders attributed to statins: A study on ninety‐six spontaneous reports in the period 1990–2005 and review of the literature
Authors:
- Isabelle MarieIMIsabelle Marie
- Network Of The French Pharmacovigilance CentersNCNetwork Of The French Pharmacovigilance Centers
- 29 February 2008
- journal article
- review article
- Published by Wiley in Arthritis Care & Research
- Vol. 59 (3) , 367-372
Abstract
Objective: To date, statins have more often been considered a safe medication. However, with the wider use of statins, severe side effects have also been reported to occur in statin‐treated patients, especially myositis and rhabdomyolysis. Currently, however, statin‐associated tendon impairment has only been described anecdotally. The aim of this retrospective study was to evaluate tendon manifestations occurring in statin‐treated patients.Methods: All reports in which a statin was listed spontaneously as a causative suspect medication of tendon complications in the network of the 31 French Pharmacovigilance Centers from 1990–2005 were included in this study. Data collection included patient characteristics and tendon adverse effects (time to onset of adverse effects, pattern, site of injury, and outcome). The percentage of the reports was further calculated for each statin.Results: Data were collected from 96 patients with a median age of 56 years; patients exhibited tendinitis (n = 63) and tendon rupture (n = 33). Tendinopathy more often occurred within the first year after statin initiation (59%). Tendon manifestations were related to atorvastatin (n = 35), simvastatin (n = 30), pravastatin (n = 21), fluvastatin (n = 5), and rosuvastatin (n = 5). Statin was reinitiated in 7 patients, resulting in recurrence of tendinopathy in all cases.Conclusion: Our series suggests that statin‐attributed tendinous complications are rare, considering the huge number of statin prescriptions. We suggest that prescribers should be aware of tendinous complications related to statins, particularly in risky situations, including physical exertion and association with medications known to increase the toxicity of statins.Keywords
This publication has 39 references indexed in Scilit:
- HMG CoA reductase inhibitors (statins) for dialysis patients2004
- Safety of StatinsCirculation, 2004
- Effets indésirables des statinesTherapies, 2003
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemiaJACC, 2002
- Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease PreventionCurrent Medical Research and Opinion, 2002
- Rationale, Design, and Baseline Characteristics of a Trial Comparing Aggressive Lipid Lowering With Atorvastatin Versus Revascularization Treatments (AVERT) fn1fn1This work is supported by a grant from Parke-Davis Pharmaceutical Research, a Division of Warner-Lambert Company, Ann Arbor, Michigan.The American Journal of Cardiology, 1997
- Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)The American Journal of Cardiology, 1995
- Inhalation of levomepromazine in severe acute asthmaThe Lancet, 1994
- Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)The American Journal of Cardiology, 1991